Study: Melanoma Overdiagnosis Is on the Rise in White People
More than half of all melanoma diagnoses among white Americans may be overdiagnoses, according to a new study in BMJ Evidence-Based Medicine. For the study, researchers collected incidence and mortality data from the Surveillance, Epidemiology and End Results 9 registries database. They also used DevCan software to calculate the cumulative lifetime risk of being diagnosed with melanoma between […]
Arcutis’ Zoryve Foam Is Now Available for Seb Derm Treatment in the U.S.
Arcutis Biotherapeutics, Inc.’s ZORYVE topical foam, 0.3%, is now officially available for the treatment of seborrheic dermatitis. The U.S. Food and Drug Administration (FDA) approved ZORYVE foam for the treatment of seborrheic dermatitis in individuals 9 years of age and older on December 15, 2023. Roflumilast foam (Zoryve, Arcutis) will be available via wholesaler and pharmacy […]
Health Canada Approves Galderma’s Restylane SHAYPE for Chin Augmentation
Health Canada has given its nod to Restylane SHAYPE, a hyaluronic acid (HA) injectable designed for temporary augmentation of the chin region. Galderma Restylane SHAYPE will be available in Canada as of February 2024. Other regulatory reviews around the world are ongoing, the Company reports. Powered by new NASHA HD technology from Galderma, Restylane SHAYPE has the highest G’ (“G […]
Caught Red-Handed: Exposing the Secret Life of CD4+ T Cells as Melanoma Warriors
In addition to their role in activating other immune cells, CD4+ T cells may help control melanoma, according to new research in Science Immunology. Researchers used microscopic live imaging to visualize the activities and interactions of CD4+ T cells with other cell types in the tumor microenvironment. “Our in-depth study, using animal models, unraveled the complex biology of CD4+ […]
Breaking News from Maui Derm: Research Supports the Safety and Efficacy of Delgocitinib in CHE
Delgocitinib cream continues to perform well in chronic hand eczema (CHE), with limited systemic exposure, according to two studies presented at the 2024 Maui Dermatology conference. Leo Pharma’s Delgocitinib is an investigational topical pan–Janus kinase inhibitor that inhibits activation of the JAK-STAT pathway. In one study, researchers reported significant improvements in both clinician-assessed (Investigator Global Assessment or […]
Eye on Itch: Evommune Initiaties Phase I Study of EVO756 in CSU
Evommune, Inc. is initiating its Phase 1 first-in-human study, evaluating EVO756 in chronic spontaneous urticaria (CSU). By blocking MRGPRX2 activation and degranulation of mast cells, EVO756 has the potential to be a first-in-class oral treatment for a variety of mast cell-mediated diseases, including chronic spontaneous urticaria and inflammatory itch. The Phase 1 study is a […]
New Insights on the Role of PD-1 in Merkel Cell Carcinoma
Programmed cell death 1 (PD-1) inhibitors have been approved for treating various types of cancer, but PD-1 functions can vary between different cell and cancer types, either promoting or suppressing disease progression. Merkel cell carcinoma (MCC) responds well to immune checkpoint inhibitor therapy, but it unknown if MCC cells express PD-1 themselves. In addition, researchers […]
Galderma’s Liquid Toxin Continues to Impress in Phase 3 Program
One dose of RelabotulinumtoxinA significantly improves both frown lines and crow’s feet, when treated alone or simultaneously, and the results last for six months, according to research presented at the TOXINS 2024 International Conference in Berlin. RelabotulinumtoxinA is a ready-to-use liquid botulinum toxin A which avoids the need to reconstitute from powder and eliminates variability, […]
Maui Derm News: One TheraClearX Treatment Reduces Cystic and Papular Acne Lesions
Just one treatment with STRATA’s TheraClearX helps clear cystic and papular acne, according to a poster slated to be presented at the Maui Derm 2024 Meeting to be held at the Grand Wailea in Maui, Hawaii from January 22-26, 2024. TheraClearX employs photopneumatic technology to deliver intense pulsed light utilizing vacuum technology with an additional needle insert; the vacuum pulls […]
Breaking Business News: Sun Pharma to Buy Remaining Stake in Taro
Sun Pharma is picking up all the shares in Taro Pharmaceuticals that it doesn’t already own. The two companies have entered into a definitive merger agreement in which Sun Pharma, Taro’s controlling shareholder, has agreed to acquire all of the outstanding ordinary shares of Taro other than the shares already held by Sun Pharma or […]